Uniting Brand-New Faces Across Biotech & Pharma to Capitalize on Ground-Breaking Progress & Accelerate a New Era of Neurodegenerative Therapeutics
In 2025, the spotlight is on neurodegenerative drug development, driven by the triumph of Lecanemab and Donanemab, coupled with rapid advancements to enable presymptomatic diagnosis, reinvigorating the space with new targets, modalities, and technologies. Meanwhile significant advancements to target the likes of α-synuclein, NLRP3 and GBA suggest only a matter of time until a disease-modifying therapy emerges on the scene for Parkinson’s too.
Capitalizing on a new era of revitalized hope and momentum, the 13th Alzheimer’s & Parkinson’s Drug Development Summit returns as the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical, regulatory, and commercial development.
Join industry’s premier gathering of 150+ Alzheimer’s and Parkinson’s experts, with pioneering insights from the likes of Eisai, Eli Lilly, Biogen, and Roche, as they address their most pressing challenges in a collaborative atmosphere to spearhead the next wave of more truly transformative neurodegenerative therapeutics.
World-Class Speaker Faculty Includes:
Ivana Rubino
Vice President, Head of Global Medical for Neuropsychiatry & Alzheimer's Disease
Biogen
Malu Tansey
Director of the Center for Translational Research in Neurodegenerative Disease
University of Florida
Attending Companies Included:
Thoughts from your 2025 Expert Speakers:
“At ProMIS Neurosciences, we appreciate the size of the APDD meeting and the variety of participants. There is ample opportunity to make connections and discuss important issues among large and small groups, and large and small organizations.”
– Neil Cashman, Chief Scientific Officer, ProMIS Neurosciences
"I am excited to discuss new targeting opportunities beyond the recently approved beta amyloid therapies with researchers and industry experts in the field."
- Kate Planey, Chief Executive Officer, Acelot
"I am excited to discuss new targeting opportunities beyond the recently approved beta amyloid therapies with researchers and industry experts in the field."
- Kate Planey, Chief Executive Officer, Acelot
“I am excited to discuss breaking research developments in the field of AD with experts in the field from industry and academia.”
- Urs Langen, Lab Head & Research Project Leader, Roche
Our Partners:
Our Media Partners:
Other Events in the World CNS Series
